EA200900738A1 - Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1 - Google Patents

Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1

Info

Publication number
EA200900738A1
EA200900738A1 EA200900738A EA200900738A EA200900738A1 EA 200900738 A1 EA200900738 A1 EA 200900738A1 EA 200900738 A EA200900738 A EA 200900738A EA 200900738 A EA200900738 A EA 200900738A EA 200900738 A1 EA200900738 A1 EA 200900738A1
Authority
EA
Eurasian Patent Office
Prior art keywords
lage
eso
tensions
tumor
slip
Prior art date
Application number
EA200900738A
Other languages
English (en)
Other versions
EA016818B1 (ru
Inventor
Норман Блэйс
Мартин Бойер
Винсент Бришар
Жамиля Луаэд
Денис Мартин
Реми М. Палмантье
Клеман Риукс
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0700759A external-priority patent/GB0700759D0/en
Priority claimed from GB0709707A external-priority patent/GB0709707D0/en
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA200900738A1 publication Critical patent/EA200900738A1/ru
Publication of EA016818B1 publication Critical patent/EA016818B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Abstract

Предложены слитые белки, содержащие антиген, имеющий происхождение из NY-ESO-1, связанный с антигеном, имеющим происхождение из LAGE-1, которые могут дополнительно содержать носители, партнеры по слиянию или тому подобное. Также предложены способы получения таких слитых белков, изготовления их в виде препарата и их применения. Такие белки полезны в качестве компонентов вакцин для индукции иммунного ответа против ряда клеток, несущих раковые антигены,
EA200900738A 2007-01-15 2008-01-11 Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1 EA016818B1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0700759A GB0700759D0 (en) 2007-01-15 2007-01-15 Novel fusion protein
US91484807P 2007-04-30 2007-04-30
US91492507P 2007-04-30 2007-04-30
GB0709707A GB0709707D0 (en) 2007-05-21 2007-05-21 Novel fusion protein
PCT/US2008/050879 WO2008089074A2 (en) 2007-01-15 2008-01-11 Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1

Publications (2)

Publication Number Publication Date
EA200900738A1 true EA200900738A1 (ru) 2010-02-26
EA016818B1 EA016818B1 (ru) 2012-07-30

Family

ID=41111108

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200900738A EA016818B1 (ru) 2007-01-15 2008-01-11 Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1

Country Status (15)

Country Link
EP (1) EP2118128B1 (ru)
JP (1) JP2010532656A (ru)
KR (1) KR20090122426A (ru)
BR (1) BRPI0806501A2 (ru)
CA (1) CA2674458A1 (ru)
DK (1) DK2118128T3 (ru)
EA (1) EA016818B1 (ru)
ES (1) ES2398492T3 (ru)
HR (1) HRP20130022T1 (ru)
MX (1) MX2009007572A (ru)
PE (1) PE20081687A1 (ru)
PL (1) PL2118128T3 (ru)
SI (1) SI2118128T1 (ru)
TW (1) TW200902049A (ru)
WO (1) WO2008089074A2 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008308474A (ja) * 2007-06-18 2008-12-25 Nitto Denko Corp 抗原ペプチド製剤の調製方法
EP2408933A2 (en) 2009-03-17 2012-01-25 MDxHealth SA Improved detection of gene expression
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
US20140322344A1 (en) * 2011-08-31 2014-10-30 National University Corporation Tokyo Medical And Dental University Vaccine preparation for cancer treatment
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
CN109893648A (zh) 2013-06-28 2019-06-18 奥克兰联合服务有限公司 氨基酸缀合物和肽缀合物及缀合方法
EP3053592A4 (en) 2013-10-01 2017-09-06 Mie University T cell-inducing vaccine containing interepitope sequence promoting antigen presentation
JP2018505152A (ja) 2014-12-23 2018-02-22 アン ブリンブル マーガレット アミノ酸複合体及びペプチド複合体ならびにそれらの使用
EP3419962A4 (en) 2016-02-26 2020-03-11 Auckland Uniservices Limited AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION METHOD

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06205672A (ja) * 1992-03-19 1994-07-26 Nippon Zeon Co Ltd 日本脳炎ウイルス及びｂ型肝炎ウイルスの表面抗原タンパク質の抗原部位を持つキメラタンパク質の製造法、およびそれに用いる組み換えバキュロウイルス
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
EP1272633B1 (en) * 2000-03-30 2011-04-27 Dendreon Corporation Compositions and methods for dendritic cell-based immunotherapy
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens
AU2004314347B2 (en) * 2003-12-24 2011-05-19 Aduro Biotech, Inc. Recombinant nucleic acid molecules encoding fusion proteins comprising antigens and bacterial secretory signal polypeptides, expression cassettes, and bacteria, and methods of use thereof
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
CN101090974B (zh) * 2004-11-16 2011-05-11 克鲁塞尔荷兰公司 包含重组病毒载体的多价疫苗
CA2653402A1 (en) * 2006-05-26 2007-12-06 Glaxosmithkline Biologicals S.A. Method
NZ578285A (en) * 2007-01-15 2011-12-22 Glaxosmithkline Biolog Sa Fusion protein comprising a prame linked to a immunological fusion partner protein and additional amino acids at the n terminal end of the fusion partner sequence

Also Published As

Publication number Publication date
KR20090122426A (ko) 2009-11-30
TW200902049A (en) 2009-01-16
PE20081687A1 (es) 2008-12-25
WO2008089074A9 (en) 2012-07-12
MX2009007572A (es) 2009-10-13
DK2118128T3 (da) 2013-02-18
BRPI0806501A2 (pt) 2014-04-22
JP2010532656A (ja) 2010-10-14
WO2008089074A3 (en) 2008-12-31
PL2118128T3 (pl) 2013-03-29
HRP20130022T1 (hr) 2013-02-28
EA016818B1 (ru) 2012-07-30
EP2118128A2 (en) 2009-11-18
WO2008089074A2 (en) 2008-07-24
ES2398492T3 (es) 2013-03-19
EP2118128B1 (en) 2012-11-07
CA2674458A1 (en) 2008-07-24
SI2118128T1 (sl) 2013-02-28

Similar Documents

Publication Publication Date Title
EA200900738A1 (ru) Слитые белки, содержащие антигены отторжения опухоли ny-eso-1 и lage-1
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
CY1120305T1 (el) Συνθεση εμβολιου περιεχουσα συνθετικο ανοσοενισχυτικο
CY1119366T1 (el) Καινοτομος ανοσοθεραπεια εναντι διαφορων ογκων συμπεριλαμβανομενου του γαστρεντερικου και του γαστρικου καρκινου
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
WO2007039192A3 (en) Compositions and methods for treating tumors presenting survivin antigens
EA201791150A1 (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака
CY1107973T1 (el) Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων
DOP2013000029A (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
WO2016176624A3 (en) Porcine pestvirus, vaccines, and assays
ATE494303T1 (de) An humane leukozytenantigen-(hla-)klasse-i- oder ii-moleküle bindende tumorassoziierte peptide und damit im zusammenhang stehender impfstoff gegen krebs
FR2919804B1 (fr) Composition et vaccin therapeutique anti-tumoral
DK2280721T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
EA201000207A1 (ru) Новые иммуногенные эпитопы для иммунотерапии
WO2006071983A3 (en) Use of compositions comprising various tumor-associated antigens as anti-cancer vaccines
UA97092C2 (ru) T-клеточные эпитопы с раково-эмбрионального антиген-незрелого рецепторного белка ламинина и их медицинское применение
BRPI0416141B8 (pt) anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
EA200900795A1 (ru) Вакцина
PL1951300T3 (pl) Zmiana równowagi TH1/TH2 w szczepionkach typu split przeciwko grypie zawierających adjuwant
CR10143A (es) Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer
EP3792628A3 (en) Methods for predicting the usefulness of neoantigens for immunotherapy
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene
MX2021000853A (es) Vacunas individualizadas para el cancer.
CY1113720T1 (el) Πρωτεϊνες συντηξης που περιλαμβανουν τα αντιγονα ny-eso-1 και lage-1 απορριψης ογκου

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU